TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell
Portfolio Pulse from
TG Therapeutics reported strong Q3 revenue for Briumvi, a treatment for multiple sclerosis, but missed EPS expectations due to higher non-cash compensation and R&D investments. Despite raising full-year revenue guidance, shares fell due to deceleration in revenue growth and competitive pressures.
November 05, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TG Therapeutics' Q3 earnings report showed strong revenue growth for Briumvi but missed EPS expectations due to increased non-cash compensation and R&D investments. Despite raising full-year revenue guidance, shares fell due to deceleration in revenue growth and competitive pressures.
The company's strong revenue growth for Briumvi was overshadowed by an EPS miss, primarily due to higher non-cash compensation and R&D investments. The deceleration in revenue growth and competitive pressures from Ocrevus and Kesimpta likely contributed to the negative market reaction, despite the raised full-year revenue guidance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100